产品名称

Cannabidiol - CBD

产品货号

Axon 1234 CAS [13956-29-1] MF C21H30O2MW 314.46 Purity: 97% Soluble in DMSO Description Cannabidiol does not bind to CB1 or CB2 receptors but it does block the effects of cannabinoid agonists by an unknown indirect way. Recently it was found to be an antagonist at the putative new cannabinoid receptor, GPR55, a GPCR expressed in the caudate nucleus and putamen; a promising therapeutic agent for the treatment of psychosis, hyperalgesia, seizures, and stroke References Certificates Categories Extra info A Thomas et al. Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Br. J. Pharmacol. 2007,150 (5), 613–23. E Ryberg et al. The orphan receptor GPR55 is a novel cannabinoid receptor. Br. J. Pharmacol. 2007, 152, 1092–1101. LE Long et al. The pharmacological actions of cannabidiol. Drugs Fut. 2005, 30(7), 747-753. Certificate of Analysis Material Safety Data Sheet CNS Pain & Inflammation GPR55 A15 GPR55 antagonist Chemical name 2-((1R,6R)-6-Isopropenyl-3-methyl-cyclohex-2-enyl)-5-pentyl-benzene-1,3-diol Parent CAS No. [13956-29-1] Order Size Unit Price Stock 10 mg €105.00 In Stock

产品价格

现货询价，电话：010-67529703

产品规格

产品品牌

axonmedchem

产品概述

产品详情

Cannabidiol - CBD

Based on 15 reference(s) in Google Scholar 8 10 15

Axon 1234

CAS [13956-29-1]

MF C21H30O2
MW 314.46

Purity: 97%
Soluble in DMSO

Cannabidiol

Description

Cannabidiol does not bind to CB1 or CB2 receptors but it does block the effects of cannabinoid agonists by an unknown indirect way. Recently it was found to be an antagonist at the putative new cannabinoid receptor, GPR55, a GPCR expressed in the caudate nucleus and putamen; a promising therapeutic agent for the treatment of psychosis, hyperalgesia, seizures, and stroke